Helical Fusion Signs Japan’s First Power Purchase Agreement for Fusion Energy with Aoki Super
8.12.2025 11:00:00 EET | Business Wire | Press release
Helical Fusion Co., Ltd. (Headquarters: Tokyo, Japan; “Helical Fusion”), a company developing a commercially viable Helical Stellarator power plant under its “Helix Program”, has signed a Power Purchase Agreement (PPA) with Aoki Super Co., Ltd. (Headquarters: Aichi, Japan; “Aoki Super”), a major regional supermarket chain in central Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207372064/en/
Takaya Taguchi (left), CEO of Helical Fusion Co., Ltd. , and Masayuki Kono (right) Managing Director and Head of Administration Division of Aoki Super Co., Ltd. at the press conference held on December 8, 2025
This marks the first fusion-energy PPA ever signed in Japan, representing a concrete step forward in the real-world adoption of fusion energy and signaling growing demand-side engagement in the emerging fusion energy value chain.
Significance of This Agreement
Fusion energy—generated by reproducing on Earth the same nuclear fusion reactions that power the sun—is widely expected as a high-efficiency, sustainable energy source. Since the concept was proposed in the 1930s, global attention has focused primarily on the scientific and technical challenges of realizing fusion. However, for fusion to become part of real-world energy infrastructure, the presence of customers willing to procure fusion-generated electricity and to integrate it into their long-term decarbonization strategies is essential.
Under the Helix Program, Helical Fusion begins with a simple premise: fusion must function as a reliable power source. Working backward from this goal, the company defined three non-negotiable requirements—steady-state operation, net electricity, and maintainability—and selected the Helical Stellarator as the only design capable of meeting all three with existing technology. Helical Fusion’s approach is grounded in over 60 years of Japanese national fusion research, enabling the company to outline a credible technical pathway to continuous, net-electricity operation.
The newly signed PPA demonstrates that this development plan has been concretely evaluated by a real electricity consumer: Aoki Super, which requires large amounts of electricity every day to operate its store networks. Both companies share the view that fusion energy can underpin environmentally responsible retail operations that support everyday life.
The agreement is also an important milestone for the Helix Program, whose distinctive strength lies in mobilizing Japan’s entire industrial value chain—from advanced manufacturing to end-users—to accelerate the realization of fusion energy.
About Aoki Super Co., Ltd.
Founded in 1941 and headquartered in Nagoya, Aoki Super operates 50 community-based supermarkets across Aichi Prefecture, Japan. As a food retailer operating electricity-intensive stores, the company views climate change—such as shifting agricultural production regions and rising seawater temperatures affecting marine resources—as a critical challenge.
In July 2025, as part of its long-term commitment to sustainability and environmental stewardship, Aoki Super made a strategic investment in Helical Fusion.
About Helical Fusion Co., Ltd.
Helical Fusion is a Japan-based fusion company developing the world’s first commercially viable, net-electricity fusion power plant, leveraging the Helical Stellarator and inheriting more than 60 years of national fusion research.
To date, Helical Fusion has raised JPY 5.2 billion (≈ USD 34 million) in equity funding, bringing its cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion).
About the Helix Program
The Helix Program targets the launch of the world’s first commercially viable fusion power plant in the 2030s through its Fusion Pilot Plant, Helix KANATA. The program defines three essential requirements for commercially viable fusion power:
Steady-state operation: 24/7/365 stable performance
Net electricity output: generating more energy than it consumes
Maintainability: regular, efficient component maintenance
The Helical Stellarator is uniquely capable of meeting all three criteria with existing technologies. The Helix Program aims to be the world’s first initiative to realize all of these requirements by the 2030s.
Company Details
- Business: Development of commercial fusion reactors and related technologies
- Founded: October 2021
- Website: https://www.helicalfusion.com/en
- YouTube: https://www.youtube.com/@HelicalFusion
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207372064/en/
Contacts
Media Contact
Email: contact@helicalfusion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom